Basilea Pharmaceutica AG (OTCMKTS:BPMUF) Sees Significant Drop in Short Interest

Basilea Pharmaceutica AG (OTCMKTS:BPMUF) was the target of a significant drop in short interest during the month of November. As of November 15th, there was short interest totalling 26,700 shares, a drop of 11.3% from the October 31st total of 30,100 shares. Based on an average daily volume of 0 shares, the days-to-cover ratio is presently ∞ days.

Analyst Upgrades and Downgrades

Separately, HC Wainwright upgraded shares of Basilea Pharmaceutica to a “strong-buy” rating in a research note on Monday, September 23rd.

Basilea Pharmaceutica Price Performance

Shares of BPMUF remained flat at $52.83 during midday trading on Friday. The stock has a fifty day simple moving average of $52.39 and a 200 day simple moving average of $49.90. Basilea Pharmaceutica has a twelve month low of $38.60 and a twelve month high of $52.83.

Basilea Pharmaceutica Company Profile

Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union.